Bioinformatics Analyses Indicate That Cathepsin G (CTSG) is a Potential Immune-Related Biomarker in Oral Squamous Cell Carcinoma (OSCC).
CTSG
bioinformatics
biomarker
immune
oral squamous cell carcinoma
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
11
2020
accepted:
18
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Plenty of studies showed that the immune system was associated with cancer initiation and progression. This study aimed to explore the prognostic biomarkers from immune-related genes (IRGs) in oral squamous cell carcinoma (OSCC). RNA-seq data were downloaded from The Cancer Genome Atlas (TCGA) and IRGs and transcription factors (TFs) were extracted. Then, the co-expression network between IRGs and TFs was constructed using the "WGCNA" package in R software. Furthermore, a gene expression signature according to IRGs was constructed to predict OSCC prognosis and its accuracy was validated by survival analysis. Subsequently, correlation analyses between risk-score and immune cells level and clinical parameters were performed. Finally, immune-related biomarkers were selected and further investigated using gain-of-function assays in vitro. A total of 32 normal cases and 317 OSCC cases were selected in our study. Differentially-expressed analysis indicated that there were 381 differentially-expressed IRGs and 62 TFs in OSCC. Among them, 25 TFs and 21 IRGs were enrolled in the co-expression network. Furthermore, we found that gene expression signature on the basis of 10 IRGs could predict the prognosis accurately and a high-risk score based on gene expression signature meant a high T classification, terminal clinical stage, and low immune cells level in OSCC. Finally, cathepsin G (CTSG) was identified as a potential immune-related biomarker and therapeutic target in OSCC. In conclusion, IRGs were directly involved in the development and progression of OSCC. Furthermore, CTSG was identified as a potential independent biomarker and might be an immunotherapeutic target in OSCC treatment.
Identifiants
pubmed: 33658795
doi: 10.2147/OTT.S293148
pii: 293148
pmc: PMC7920606
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1275-1289Informations de copyright
© 2021 Huang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Head Neck. 2018 Oct;40(10):2155-2165
pubmed: 29761594
Tumour Biol. 2015 Apr;36(4):2523-9
pubmed: 25613064
Clin Exp Dent Res. 2020 Apr;6(2):174-180
pubmed: 32250571
Cancer Med. 2019 Jan;8(1):80-93
pubmed: 30600646
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Cell Oncol (Dordr). 2020 Oct;43(5):763-777
pubmed: 32495292
Oral Oncol. 2009 Apr-May;45(4-5):440-6
pubmed: 18674958
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Int J Mol Sci. 2018 Sep 08;19(9):
pubmed: 30205554
Biomed Pharmacother. 2019 Apr;112:108608
pubmed: 30798120
Oncoimmunology. 2017 May 4;6(7):e1325066
pubmed: 28811959
J Oral Pathol Med. 2016 Nov;45(10):730-739
pubmed: 26850833
Leukemia. 2017 Jan;31(1):234-237
pubmed: 27573556
Clin Exp Metastasis. 2019 Dec;36(6):481-492
pubmed: 31559586
Nat Commun. 2018 May 15;9(1):1920
pubmed: 29765046
Semin Cancer Biol. 2020 Apr;61:71-83
pubmed: 31542510
Mol Carcinog. 2020 Nov;59(11):1302-1316
pubmed: 33006223
Cancer Sci. 2017 Aug;108(8):1574-1583
pubmed: 28544544
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Front Oncol. 2019 Oct 18;9:1054
pubmed: 31681590
J Dent Res. 2016 Jul;95(8):860-7
pubmed: 27013642
BMC Res Notes. 2015 Oct 14;8:569
pubmed: 26467671
Aging (Albany NY). 2020 Jun 11;12(12):11667-11684
pubmed: 32526707
Cell Oncol (Dordr). 2014 Apr;37(2):119-29
pubmed: 24599717
Ann Transl Med. 2019 May;7(9):204
pubmed: 31205922
Cancer. 2016 Feb 1;122(3):367-77
pubmed: 26540029
Oncol Rep. 2010 Jul;24(1):241-9
pubmed: 20514468
Oral Oncol. 2012 Oct;48(10):997-1006
pubmed: 22704062
J Mol Med (Berl). 2018 Jun;96(6):513-525
pubmed: 29713760
Mol Med Rep. 2019 May;19(5):4101-4108
pubmed: 30942437
J Cancer. 2020 Jan 14;11(6):1457-1467
pubmed: 32047552
Clin Cancer Res. 2019 Jul 15;25(14):4211-4223
pubmed: 30814108